6th Jul 2016 10:17
LONDON (Alliance News) - Healthcare company BTG PLC on Wednesday said the US Food & Drug Administration has approved an extension to the post-activation shelf life of the FTSE 250-listed company's Varithena varicose veins treatment.
The shelf life for the drug has been extended to 30 days from seven previously.
"This approval provides physicians with greater flexibility," said John Sylvester, corporate development officer at BTG.
"It highlights our continued work to provide a non-thermal chemical ablation solution that best fits practices' needs," he said.
BTG shares were down 0.2% to 687.50 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
BTG